Loading…
No business profile yet.
Size CHO Pharma (6586.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $480M, the 459th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$74.20 on 6 Nov 2026.
Performance Over six months the shares gained 56.5%, against -11.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue fell 46.9% over the last twelve months (peer median -2.2%); the operating margin is -17,694.3% (peer median -27.2%).
Valuation It trades at 8,168.1× enterprise value to sales against a peer median of 12.9× (most expensive of 15).
Capital Return on invested capital runs 67.0 points below its cost of capital (9.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$1.71M | NT$1.43M | NT$3.58M | NT$0 | NT$60,000 |
| Revenue growth | — | -60% | — | -100% | — |
| Gross profit | -NT$22.6M | -NT$25.5M | -NT$23.8M | -NT$28.3M | -NT$35.8M |
| EBITDA | -NT$278M | -NT$299M | -NT$223M | -NT$241M | -NT$315M |
| Net income | -NT$268M | -NT$290M | -NT$212M | -NT$306M | -NT$338M |
| Free cash flow | -NT$250M | -NT$289M | -NT$223M | -NT$293M | -NT$259M |
| Capital expenditure | NT$10.9M | NT$11.7M | NT$5.49M | NT$2.00M | NT$9.40M |
| Total debt | n/a | NT$14.6M | NT$28.9M | NT$0 | NT$11.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6586.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -38.4% | -12.5% | lowest of 21 |
| 6-month return | +56.5% | -11.3% | 2nd highest of 20 |
| Distance from 52-week high | -50.0% | -35.7% | 3rd lowest of 21 |
| Revenue growth (TTM) | -46.9% | -2.2% | 3rd lowest of 14 |
| Operating margin | -17,694.3% | -27.2% | lowest of 15 |
| EV / Sales | 8,168.1× | 12.9× | most expensive of 15 |
| ROIC minus cost of capital | -67.0 pp | -15.4 pp | 3rd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | 8,168.1× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 5.2× | 15.2% | +0.5% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | 5.2× | 6.0% | -62.3% |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 2.5× | -14.9% | -36.1% |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 18.0× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | 258.1× | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $462M | -4% | +20% | -79% | 11.4× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | 12.1× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | 28.3× | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | 98.9× | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | 3.8× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $458M | +139% | n/a | n/a | n/a | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $505M | +48% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $506M | -18% | -100% | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $507M | -11% | -1% | 26% | 13.7× | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $454M | +10% | +4% | -30% | 22.4× | 31.8% | -3.3% |
| HanchorBio 7827.TW | Taiwan | $511M | n/a | n/a | -225% | 48.0× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 2.3× | 18.2% | +7.3% |